SK284860B6 - Použitie p-aminofenolového derivátu na výrobu liečiva na liečenie neurodegeneratívnych chorôb - Google Patents

Použitie p-aminofenolového derivátu na výrobu liečiva na liečenie neurodegeneratívnych chorôb Download PDF

Info

Publication number: SK284860B6
Authority: SK; Slovakia
Prior art keywords: paracetamol; indomethacin; treatment; neurodegenerative diseases; cells
Prior art date: 1996-05-21

Application number

SK1598-98A

Other languages

English (en)

Slovak (sk)

Other versions

SK159898A3 (en

Inventor

Mario Pinza

Mario Brufani

Claudio Milanese

Original Assignee

Angelini Ricerche S. P. A. Societa Consortile

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1996-05-21

Filing date

1997-05-15

Publication date

2006-01-05

1997-05-15 Application filed by Angelini Ricerche S. P. A. Societa Consortile filed Critical Angelini Ricerche S. P. A. Societa Consortile

2000-04-10 Publication of SK159898A3 publication Critical patent/SK159898A3/sk

2006-01-05 Publication of SK284860B6 publication Critical patent/SK284860B6/sk

Links

230000004770 neurodegeneration Effects 0.000 title claims abstract description 11
PLIKAWJENQZMHA-UHFFFAOYSA-N 4-aminophenol Chemical class NC1=CC=C(O)C=C1 PLIKAWJENQZMHA-UHFFFAOYSA-N 0.000 title claims abstract description 10
208000015122 neurodegenerative disease Diseases 0.000 title claims abstract description 10
239000008194 pharmaceutical composition Substances 0.000 title description 3
238000002360 preparation method Methods 0.000 title description 2
238000004519 manufacturing process Methods 0.000 claims abstract description 17
239000003814 drug Substances 0.000 claims abstract description 13
239000000651 prodrug Chemical group 0.000 claims abstract description 9
229940002612 prodrug Drugs 0.000 claims abstract description 9
229950007008 acetaminosalol Drugs 0.000 claims abstract description 7
229910052739 hydrogen Inorganic materials 0.000 claims abstract description 5
239000001257 hydrogen Substances 0.000 claims abstract description 5
TWIIVLKQFJBFPW-UHFFFAOYSA-N acetaminosalol Chemical compound C1=CC(NC(=O)C)=CC=C1OC(=O)C1=CC=CC=C1O TWIIVLKQFJBFPW-UHFFFAOYSA-N 0.000 claims abstract description 4
-1 acetaminosalol glycine ester Chemical class 0.000 claims abstract description 4
QTGAJCQTLIRCFL-UHFFFAOYSA-N propacetamol Chemical compound CCN(CC)CC(=O)OC1=CC=C(NC(C)=O)C=C1 QTGAJCQTLIRCFL-UHFFFAOYSA-N 0.000 claims abstract description 4
229960003192 propacetamol Drugs 0.000 claims abstract description 4
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Natural products NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims abstract description 3
239000004471 Glycine Substances 0.000 claims abstract description 3
RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 claims description 40
229960005489 paracetamol Drugs 0.000 claims description 38
208000024827 Alzheimer disease Diseases 0.000 claims description 8
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 4
150000001875 compounds Chemical class 0.000 abstract description 12
125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 50
229960000905 indomethacin Drugs 0.000 description 25
210000004027 cell Anatomy 0.000 description 23
230000000694 effects Effects 0.000 description 16
102000004889 Interleukin-6 Human genes 0.000 description 10
108090001005 Interleukin-6 Proteins 0.000 description 10
229940100601 interleukin-6 Drugs 0.000 description 10
102200082402 rs751610198 Human genes 0.000 description 10
230000002757 inflammatory effect Effects 0.000 description 9
150000003180 prostaglandins Chemical class 0.000 description 9
102000004127 Cytokines Human genes 0.000 description 7
108090000695 Cytokines Proteins 0.000 description 7
210000004556 brain Anatomy 0.000 description 7
230000000295 complement effect Effects 0.000 description 7
210000003169 central nervous system Anatomy 0.000 description 6
230000007170 pathology Effects 0.000 description 6
102000013455 Amyloid beta-Peptides Human genes 0.000 description 5
108010090849 Amyloid beta-Peptides Proteins 0.000 description 5
238000003556 assay Methods 0.000 description 5
CPJSUEIXXCENMM-UHFFFAOYSA-N phenacetin Chemical compound CCOC1=CC=C(NC(C)=O)C=C1 CPJSUEIXXCENMM-UHFFFAOYSA-N 0.000 description 5
102000004169 proteins and genes Human genes 0.000 description 5
108090000623 proteins and genes Proteins 0.000 description 5
230000000638 stimulation Effects 0.000 description 5
102000000989 Complement System Proteins Human genes 0.000 description 4
108010069112 Complement System Proteins Proteins 0.000 description 4
ADEBPBSSDYVVLD-UHFFFAOYSA-N donepezil Chemical compound O=C1C=2C=C(OC)C(OC)=CC=2CC1CC(CC1)CCN1CC1=CC=CC=C1 ADEBPBSSDYVVLD-UHFFFAOYSA-N 0.000 description 4
238000002474 experimental method Methods 0.000 description 4
238000011534 incubation Methods 0.000 description 4
230000002401 inhibitory effect Effects 0.000 description 4
230000005764 inhibitory process Effects 0.000 description 4
210000002540 macrophage Anatomy 0.000 description 4
210000004498 neuroglial cell Anatomy 0.000 description 4
229940094443 oxytocics prostaglandins Drugs 0.000 description 4
230000028327 secretion Effects 0.000 description 4
230000009471 action Effects 0.000 description 3
229940079593 drug Drugs 0.000 description 3
208000005017 glioblastoma Diseases 0.000 description 3
239000001963 growth medium Substances 0.000 description 3
230000017306 interleukin-6 production Effects 0.000 description 3
238000000034 method Methods 0.000 description 3
230000001575 pathological effect Effects 0.000 description 3
229960003893 phenacetin Drugs 0.000 description 3
230000001988 toxicity Effects 0.000 description 3
231100000419 toxicity Toxicity 0.000 description 3
GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
206010012289 Dementia Diseases 0.000 description 2
230000004913 activation Effects 0.000 description 2
229940124599 anti-inflammatory drug Drugs 0.000 description 2
230000003110 anti-inflammatory effect Effects 0.000 description 2
230000015572 biosynthetic process Effects 0.000 description 2
238000013270 controlled release Methods 0.000 description 2
229960003530 donepezil Drugs 0.000 description 2
239000002158 endotoxin Substances 0.000 description 2
238000009472 formulation Methods 0.000 description 2
RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
230000028709 inflammatory response Effects 0.000 description 2
229920006008 lipopolysaccharide Polymers 0.000 description 2
238000002156 mixing Methods 0.000 description 2
239000000203 mixture Substances 0.000 description 2
230000037361 pathway Effects 0.000 description 2
230000036470 plasma concentration Effects 0.000 description 2
206010039073 rheumatoid arthritis Diseases 0.000 description 2
239000007787 solid Substances 0.000 description 2
210000000225 synapse Anatomy 0.000 description 2
238000003786 synthesis reaction Methods 0.000 description 2
239000003826 tablet Substances 0.000 description 2
SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 1
LOGFVTREOLYCPF-KXNHARMFSA-N (2s,3r)-2-[[(2r)-1-[(2s)-2,6-diaminohexanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxybutanoic acid Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H]1CCCN1C(=O)[C@@H](N)CCCCN LOGFVTREOLYCPF-KXNHARMFSA-N 0.000 description 1
229940100578 Acetylcholinesterase inhibitor Drugs 0.000 description 1
206010048998 Acute phase reaction Diseases 0.000 description 1
102000011767 Acute-Phase Proteins Human genes 0.000 description 1
108010062271 Acute-Phase Proteins Proteins 0.000 description 1
108020004774 Alkaline Phosphatase Proteins 0.000 description 1
102000002260 Alkaline Phosphatase Human genes 0.000 description 1
229940127291 Calcium channel antagonist Drugs 0.000 description 1
108010009685 Cholinergic Receptors Proteins 0.000 description 1
102000009109 Fc receptors Human genes 0.000 description 1
108010087819 Fc receptors Proteins 0.000 description 1
229940122459 Glutamate antagonist Drugs 0.000 description 1
108010024636 Glutathione Proteins 0.000 description 1
102000003777 Interleukin-1 beta Human genes 0.000 description 1
108090000193 Interleukin-1 beta Proteins 0.000 description 1
PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 1
FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
MKXZASYAUGDDCJ-SZMVWBNQSA-N LSM-2525 Chemical compound C1CCC[C@H]2[C@@]3([H])N(C)CC[C@]21C1=CC(OC)=CC=C1C3 MKXZASYAUGDDCJ-SZMVWBNQSA-N 0.000 description 1
102000004868 N-Methyl-D-Aspartate Receptors Human genes 0.000 description 1
108090001041 N-Methyl-D-Aspartate Receptors Proteins 0.000 description 1
PIJVFDBKTWXHHD-UHFFFAOYSA-N Physostigmine Natural products C12=CC(OC(=O)NC)=CC=C2N(C)C2C1(C)CCN2C PIJVFDBKTWXHHD-UHFFFAOYSA-N 0.000 description 1
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
210000001744 T-lymphocyte Anatomy 0.000 description 1
229930003427 Vitamin E Natural products 0.000 description 1
RRGMXBQMCUKRLH-CTNGQTDRSA-N [(3ar,8bs)-3,4,8b-trimethyl-2,3a-dihydro-1h-pyrrolo[2,3-b]indol-7-yl] n-heptylcarbamate Chemical compound C12=CC(OC(=O)NCCCCCCC)=CC=C2N(C)[C@@H]2[C@@]1(C)CCN2C RRGMXBQMCUKRLH-CTNGQTDRSA-N 0.000 description 1
102000034337 acetylcholine receptors Human genes 0.000 description 1
229960004308 acetylcysteine Drugs 0.000 description 1
239000013543 active substance Substances 0.000 description 1
230000004658 acute-phase response Effects 0.000 description 1
125000002252 acyl group Chemical group 0.000 description 1
239000000654 additive Substances 0.000 description 1
239000002671 adjuvant Substances 0.000 description 1
230000002411 adverse Effects 0.000 description 1
239000000556 agonist Substances 0.000 description 1
125000000217 alkyl group Chemical group 0.000 description 1
VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
239000003194 amino acid receptor blocking agent Substances 0.000 description 1
230000006933 amyloid-beta aggregation Effects 0.000 description 1
230000000202 analgesic effect Effects 0.000 description 1
230000001754 anti-pyretic effect Effects 0.000 description 1
239000000427 antigen Substances 0.000 description 1
102000036639 antigens Human genes 0.000 description 1
108091007433 antigens Proteins 0.000 description 1
239000003963 antioxidant agent Substances 0.000 description 1
235000006708 antioxidants Nutrition 0.000 description 1
238000011888 autopsy Methods 0.000 description 1
210000003719 b-lymphocyte Anatomy 0.000 description 1
230000008901 benefit Effects 0.000 description 1
150000003936 benzamides Chemical class 0.000 description 1
230000037396 body weight Effects 0.000 description 1
210000004958 brain cell Anatomy 0.000 description 1
239000000872 buffer Substances 0.000 description 1
239000002775 capsule Substances 0.000 description 1
230000003197 catalytic effect Effects 0.000 description 1
230000006037 cell lysis Effects 0.000 description 1
230000001413 cellular effect Effects 0.000 description 1
230000002490 cerebral effect Effects 0.000 description 1
230000001713 cholinergic effect Effects 0.000 description 1
239000003086 colorant Substances 0.000 description 1
230000024203 complement activation Effects 0.000 description 1
230000004154 complement system Effects 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
229960001985 dextromethorphan Drugs 0.000 description 1
239000012895 dilution Substances 0.000 description 1
238000010790 dilution Methods 0.000 description 1
XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 1
229960002986 dinoprostone Drugs 0.000 description 1
201000010099 disease Diseases 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
238000007876 drug discovery Methods 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
210000002889 endothelial cell Anatomy 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
235000013355 food flavoring agent Nutrition 0.000 description 1
235000003599 food sweetener Nutrition 0.000 description 1
WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
229960003180 glutathione Drugs 0.000 description 1
150000002332 glycine derivatives Chemical class 0.000 description 1
235000015220 hamburgers Nutrition 0.000 description 1
230000011132 hemopoiesis Effects 0.000 description 1
230000028993 immune response Effects 0.000 description 1
238000011065 in-situ storage Methods 0.000 description 1
230000004054 inflammatory process Effects 0.000 description 1
239000007942 layered tablet Substances 0.000 description 1
239000002502 liposome Substances 0.000 description 1
239000007788 liquid Substances 0.000 description 1
230000007774 longterm Effects 0.000 description 1
239000000463 material Substances 0.000 description 1
229960004452 methionine Drugs 0.000 description 1
229930182817 methionine Natural products 0.000 description 1
229960001952 metrifonate Drugs 0.000 description 1
210000000274 microglia Anatomy 0.000 description 1
230000003551 muscarinic effect Effects 0.000 description 1
229960002362 neostigmine Drugs 0.000 description 1
LULNWZDBKTWDGK-UHFFFAOYSA-M neostigmine bromide Chemical compound [Br-].CN(C)C(=O)OC1=CC=CC([N+](C)(C)C)=C1 LULNWZDBKTWDGK-UHFFFAOYSA-M 0.000 description 1
210000000653 nervous system Anatomy 0.000 description 1
210000002569 neuron Anatomy 0.000 description 1
229960002715 nicotine Drugs 0.000 description 1
SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 1
230000003204 osmotic effect Effects 0.000 description 1
230000001717 pathogenic effect Effects 0.000 description 1
230000002093 peripheral effect Effects 0.000 description 1
239000008177 pharmaceutical agent Substances 0.000 description 1
229960001697 physostigmine Drugs 0.000 description 1
PIJVFDBKTWXHHD-HIFRSBDPSA-N physostigmine Chemical compound C12=CC(OC(=O)NC)=CC=C2N(C)[C@@H]2[C@@]1(C)CCN2C PIJVFDBKTWXHHD-HIFRSBDPSA-N 0.000 description 1
239000000902 placebo Substances 0.000 description 1
229940068196 placebo Drugs 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
239000000047 product Substances 0.000 description 1
230000007101 progressive neurodegeneration Effects 0.000 description 1
XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 description 1
239000000018 receptor agonist Substances 0.000 description 1
229940044601 receptor agonist Drugs 0.000 description 1
102000005962 receptors Human genes 0.000 description 1
108020003175 receptors Proteins 0.000 description 1
230000009467 reduction Effects 0.000 description 1
230000001105 regulatory effect Effects 0.000 description 1
230000004044 response Effects 0.000 description 1
GWHQHAUAXRMMOT-MBANBULQSA-N rivastigmine tartrate Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O.CCN(C)C(=O)OC1=CC=CC([C@H](C)N(C)C)=C1 GWHQHAUAXRMMOT-MBANBULQSA-N 0.000 description 1
150000003839 salts Chemical class 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
241000894007 species Species 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
239000008174 sterile solution Substances 0.000 description 1
230000004936 stimulating effect Effects 0.000 description 1
239000006228 supernatant Substances 0.000 description 1
239000000829 suppository Substances 0.000 description 1
239000004094 surface-active agent Substances 0.000 description 1
239000003765 sweetening agent Substances 0.000 description 1
201000000596 systemic lupus erythematosus Diseases 0.000 description 1
229960001685 tacrine Drugs 0.000 description 1
YLJREFDVOIBQDA-UHFFFAOYSA-N tacrine Chemical compound C1=CC=C2C(N)=C(CCCC3)C3=NC2=C1 YLJREFDVOIBQDA-UHFFFAOYSA-N 0.000 description 1
238000011287 therapeutic dose Methods 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
NFACJZMKEDPNKN-UHFFFAOYSA-N trichlorfon Chemical compound COP(=O)(OC)C(O)C(Cl)(Cl)Cl NFACJZMKEDPNKN-UHFFFAOYSA-N 0.000 description 1
235000019165 vitamin E Nutrition 0.000 description 1
229940046009 vitamin E Drugs 0.000 description 1
239000011709 vitamin E Substances 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Pain & Pain Management (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Epidemiology (AREA)
Chemical Kinetics & Catalysis (AREA)
Hospice & Palliative Care (AREA)
Psychiatry (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

SK1598-98A 1996-05-21 1997-05-15 Použitie p-aminofenolového derivátu na výrobu liečiva na liečenie neurodegeneratívnych chorôb SK284860B6 (sk)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
IT96MI001013A IT1282736B1 (it)	1996-05-21	1996-05-21	Uso di derivati del p-amminofenolo per preparare composizioni farmaceutiche utili nel trattamento di malattie neurodegenerative
PCT/EP1997/002708 WO1997044020A1 (en)	1996-05-21	1997-05-15	Use of p-aminophenol derivatives for the preparation of pharmaceutical compositions useful in the treatment of neurodegenerative diseases

Publications (2)

Publication Number	Publication Date
SK159898A3 SK159898A3 (en)	2000-04-10
SK284860B6 true SK284860B6 (sk)	2006-01-05

Family

ID=11374289

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SK1598-98A SK284860B6 (sk)	1996-05-21	1997-05-15	Použitie p-aminofenolového derivátu na výrobu liečiva na liečenie neurodegeneratívnych chorôb

Country Status (19)

Country	Link
US (1)	US6043285A (de)
EP (1)	EP0946162B1 (de)
JP (1)	JP2000510859A (de)
AT (1)	ATE252897T1 (de)
AU (1)	AU723004B2 (de)
CZ (1)	CZ295875B6 (de)
DE (1)	DE69725879T2 (de)
DK (1)	DK0946162T3 (de)
EA (1)	EA003251B1 (de)
ES (1)	ES2208909T3 (de)
HU (1)	HU225536B1 (de)
IL (1)	IL127044A (de)
IT (1)	IT1282736B1 (de)
NZ (1)	NZ333232A (de)
PT (1)	PT946162E (de)
SK (1)	SK284860B6 (de)
TR (1)	TR199802384T2 (de)
WO (1)	WO1997044020A1 (de)
ZA (1)	ZA974387B (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ITMI962356A1 (it) *	1996-11-13	1998-05-13	Uni Degli Studi Di Brescia D I	Uso di composti derivati da molecole ad attivita' antinfiammatoria di tipo non steroideo per la prevenzione e il trattamento di
DE19911626A1 (de) *	1999-03-16	2000-09-28	Strathmann Ag & Co	Induktion antiinflammatorisch wirkender Proteine durch Ammoniumionen bzw. Amino-Reste
BR9904931A (pt) *	1999-10-18	2001-06-12	Sergio Teixeira Ferreira	Inibição de amiloidoses
US6664297B1 (en) *	2000-10-18	2003-12-16	Universidade Federal Do Rio De Janeiro	Methods for inhibition and dissolution of amyloidoses by administration of compositions comprising 2,4-dinitrophenol
WO2004034963A2 (en) *	2002-05-17	2004-04-29	Eisai Co., Ltd.	Methods and compositions using cholinesterase inhibitors
GB0310300D0 (en) *	2003-05-06	2003-06-11	Univ Belfast	Nanocomposite drug delivery composition
US20090238763A1 (en)	2006-07-09	2009-09-24	Chongxi Yu	High penetration compositions and uses thereof
US20090221703A1 (en) *	2006-07-09	2009-09-03	Chongxi Yu	High penetration composition and uses thereof
EP3388417A1 (de) *	2006-09-03	2018-10-17	Techfields Biochem Co. Ltd	Positiv geladene, wasserlösliche prodrugs von acetaminophen und verwandten verbindungen mit einer sehr hohen hautpenetrationsrate
JP2010529101A (ja)	2007-06-04	2010-08-26	テックフィールズインコーポレイテッド	非常に速い皮膚及び膜浸透速度を有するｎｓａｉａプロドラッグ及びその新規医薬使用
JP5757864B2 (ja) *	2008-05-20	2015-08-05	ニューロジェシックス，インコーポレイテッド	水溶性アセトアミノフェン類似体
AU2009249069A1 (en)	2008-05-20	2009-11-26	Neurogesx, Inc.	Carbonate prodrugs and methods of using the same
CN108191846B (zh)	2008-12-04	2021-08-20	于崇曦	高穿透性组合物及其应用
HK1207562A1 (en)	2012-01-18	2016-02-05	苏州泰飞尔医药有限公司	High penetration prodrug compositions and pharmaceutical composition thereof for treatment of pulmonary conditions
JP5855599B2 (ja) *	2013-04-30	2016-02-09	テックフィールズバイオケムカンパニーリミテッド	非常に速い皮膚浸透率を有するアセトアミノフェン及び関連化合物の正荷電水溶性プロドラッグ
JP5997658B2 (ja) *	2013-05-08	2016-09-28	テックフィールズインコーポレイテッド	非常に速い皮膚及び膜浸透速度を有するｎｓａｉａプロドラッグ及びその新規医薬使用
JP6165816B2 (ja) *	2015-10-01	2017-07-19	テックフィールズバイオケムカンパニーリミテッド	非常に速い皮膚浸透率を有するアセトアミノフェン及び関連化合物の正荷電水溶性プロドラッグ
CN115835862B (zh) *	2020-07-10	2026-01-02	广东横琴新创益生物医药有限公司	治疗阿尔茨海默病的莫达非尼组合

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5192753A (en) *	1991-04-23	1993-03-09	Mcgeer Patrick L	Anti-rheumatoid arthritic drugs in the treatment of dementia
US5472983A (en) *	1994-04-14	1995-12-05	Centaur Pharmaceuticals, Inc.	Benzamide-containing pharmaceutical compositions
US5643960A (en) *	1994-04-15	1997-07-01	Duke University	Method of delaying onset of alzheimer's disease symptoms
US5756548A (en) *	1995-04-03	1998-05-26	Centaur Pharmaceuticals, Inc.	Acetamidobenzamide compounds for neurodegenerative disorders

1996
- 1996-05-21 IT IT96MI001013A patent/IT1282736B1/it active IP Right Grant
1997
- 1997-05-15 DE DE69725879T patent/DE69725879T2/de not_active Expired - Fee Related
- 1997-05-15 ES ES97925950T patent/ES2208909T3/es not_active Expired - Lifetime
- 1997-05-15 TR TR1998/02384T patent/TR199802384T2/xx unknown
- 1997-05-15 CZ CZ19983749A patent/CZ295875B6/cs not_active IP Right Cessation
- 1997-05-15 US US09/147,280 patent/US6043285A/en not_active Expired - Fee Related
- 1997-05-15 NZ NZ333232A patent/NZ333232A/xx unknown
- 1997-05-15 DK DK97925950T patent/DK0946162T3/da active
- 1997-05-15 EA EA199801028A patent/EA003251B1/ru not_active IP Right Cessation
- 1997-05-15 WO PCT/EP1997/002708 patent/WO1997044020A1/en not_active Ceased
- 1997-05-15 SK SK1598-98A patent/SK284860B6/sk not_active IP Right Cessation
- 1997-05-15 JP JP09541586A patent/JP2000510859A/ja active Pending
- 1997-05-15 HU HU9904027A patent/HU225536B1/hu not_active IP Right Cessation
- 1997-05-15 PT PT97925950T patent/PT946162E/pt unknown
- 1997-05-15 AT AT97925950T patent/ATE252897T1/de not_active IP Right Cessation
- 1997-05-15 IL IL12704497A patent/IL127044A/xx not_active IP Right Cessation
- 1997-05-15 EP EP97925950A patent/EP0946162B1/de not_active Expired - Lifetime
- 1997-05-15 AU AU30923/97A patent/AU723004B2/en not_active Ceased
- 1997-05-20 ZA ZA9704387A patent/ZA974387B/xx unknown

Also Published As

Publication number	Publication date
PT946162E (pt)	2004-03-31
EA199801028A1 (ru)	1999-06-24
HU225536B1 (en)	2007-02-28
DE69725879D1 (de)	2003-12-04
ITMI961013A0 (de)	1996-05-21
CZ374998A3 (cs)	1999-04-14
WO1997044020A1 (en)	1997-11-27
TR199802384T2 (xx)	1999-03-22
ES2208909T3 (es)	2004-06-16
DE69725879T2 (de)	2004-09-02
AU3092397A (en)	1997-12-09
IT1282736B1 (it)	1998-03-31
JP2000510859A (ja)	2000-08-22
HUP9904027A2 (hu)	2000-05-28
SK159898A3 (en)	2000-04-10
EP0946162B1 (de)	2003-10-29
EA003251B1 (ru)	2003-02-27
ZA974387B (en)	1997-12-23
IL127044A0 (en)	1999-09-22
DK0946162T3 (da)	2004-03-01
AU723004B2 (en)	2000-08-17
ITMI961013A1 (it)	1997-11-21
ATE252897T1 (de)	2003-11-15
HUP9904027A3 (en)	2000-07-28
NZ333232A (en)	2000-08-25
CZ295875B6 (cs)	2005-11-16
US6043285A (en)	2000-03-28
EP0946162A1 (de)	1999-10-06
IL127044A (en)	2001-03-19

Legal Events

Date	Code	Title	Description
2010-02-08	MM4A	Patent lapsed due to non-payment of maintenance fees	Effective date: 20090515

Publication	Publication Date	Title
SK159898A3 (en)	2000-04-10	Use of p-aminophenol derivatives for the preparation of pharmaceutical compositions useful in the treatment of neurodegenerative diseases
SK279521B6 (sk)	1998-12-02	Použitie rapamicínu
HUE035105T2 (en)	2018-05-02	A composition comprising nicotine and opipramole and its use
KR20060123748A (ko)	2006-12-04	통증의 치료, 변형 및 관리를 위한 면역조절 화합물을포함하는 조성물 및 이의 사용 방법
KR20160067103A (ko)	2016-06-13	신경 장애를 치료하기 위한 토라세미드 및 바클로펜을 포함하는 조성물
ES2210120T3 (es)	2004-07-01	Diacereina para uso en el tratamiento de la psoriasis.
US6362227B1 (en)	2002-03-26	Methods for the treatment of tinnitus and other disorders using R(−)ketoptofen
US20070054886A1 (en)	2007-03-08	Ras antagonists for treating neurodegenerative disorders
KR20050072113A (ko)	2005-07-08	통증의 치료, 조절 및 관리를 위한 선택적 시토킨 억제약물의 사용 방법 및 이를 포함하는 조성물
DE60316297T2 (de)	2008-06-19	Verbindungen, die zur behandlung von erkrankungen, die auf antiangiogene therapie ansprechen, nützlich sind
US4190672A (en)	1980-02-26	Method and compositions of treating Parkinsonisms with levodopa and 3',4'-dihydroxy-2-methylisopropiophenone
ITMI952242A1 (it)	1997-05-01	Composizione farmaceutica per il trattamento delle malattie autoimmuni
JP2011121975A (ja)	2011-06-23	線維筋痛症に伴う疼痛を改善するための線維筋痛症に伴う疼痛改善用医薬組成物
EP1154766A2 (de)	2001-11-21	Verwendung von r-arylpropionsäuren zur herstellung von arzneimitteln, zur behandlung von erkrankungen bei mensch und tier, welche durch die hemmung der aktivierung von nf-kappa b therapeutisch beeinflusst werden können
CN117899098B (zh)	2024-05-17	稀有人参皂苷CMx在制备用于预防和/或治疗2型炎症性疾病的药物中的应用
Csapo	1977	Inhibition of prostaglandin synthesis and contractility in the rabbit and rat uterus by ibuprofen
RU2160102C2 (ru)	2000-12-10	Применение бензидамина для лечения патологических состояний, вызванных фно
DE2841170A1 (de)	1980-04-03	Hypnotikum
JPH07505128A (ja)	1995-06-08	局所投与用薬学的組成物の調整の為の公知化合物の使用
WO2022007578A1 (zh)	2022-01-13	治疗阿尔茨海默病的组合及其应用
JPH11106337A (ja)	1999-04-20	乾癬の処置剤
Rizk et al.	2001	Comparison of the inhibitory effects of cromakalim and pinacidil (potassium channel openers) with those of oxybutynin on stimulated guinea pig and rabbit detrusor muscle strips
US20120035265A1 (en)	2012-02-09	Compositions, methods, and devices for the treatment of dysmenorrhea
DE19545180A1 (de)	1997-06-05	Methode und Zusammensetzung einer topischen Therapie der Schmerzsymptomatik bei Rheuma, Arthritis und Arthrose
JP2022067848A (ja)	2022-05-09	経鼻投与用医薬組成物